Clinical Trials Logo

Prostatic Hyperplasia clinical trials

View clinical trials related to Prostatic Hyperplasia.

Filter by:

NCT ID: NCT02645890 Completed - Clinical trials for Benign Prostatic Hyperplasia

Study to Compare the Safety and Pharmacokinetics of CKD-397

CKD-397
Start date: November 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to compare the safety and pharmacokinetics profiles of CKD-397 in healthy male volunteers.

NCT ID: NCT02639442 Completed - Clinical trials for Benign ProstaticHyperplasia (BPH)

Clinical Study for the Evaluation of the Safety and Initial Performance of the ClearRing System for the Treatment of Benign Prostatic Hyperplasia

Start date: December 2015
Phase: N/A
Study type: Interventional

The ProArc Medical ClearRing™ system is a prostatic reshaping device that is designed to treat Lower Urinary Tract Symptoms (LUTS) due to BPH. During the procedure an implant is delivered into the prostate tissue obstructing the urethra and restricting urine flow. The delivery system uses an electro-cutting blade to perform a circular and superficial incision, in which the implant is placed. Such an implant, with the shape of an open ring, expands the obstructed area, reducing the fluid obstruction through the prostatic urethra.

NCT ID: NCT02637960 Completed - Nocturia Clinical Trials

Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)

EQUINOC
Start date: March 2016
Phase: Phase 2/Phase 3
Study type: Interventional

This study will investigate the efficacy and safety of fedovapagon in the treatment of nocturia in men with BPH.

NCT ID: NCT02634489 Completed - Healthy Clinical Trials

EC905 Pharmacokinetic Profile Study

Start date: March 2009
Phase: Phase 1
Study type: Interventional

A study to compare the pharmacokinetics of tamsulosin HCl and solifenacin succinate after co-administration of single entity tablets and of the combination tablet EC905 under steady state conditions at three dose strengths.

NCT ID: NCT02625545 Completed - Clinical trials for Benign Prostatic Hyperplasia (BPH)

Study of Median Lobe Prostatic UroLift Procedure

Start date: February 17, 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of using UroLift in subjects with a prostatic median lobe enlargement due to benign prostatic hyperplasia (BPH).

NCT ID: NCT02615782 Completed - Clinical trials for Benign Prostatic Hypertrophy (BPH)

A Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-397 in Healthy Male Subjects

Start date: December 2015
Phase: Phase 1
Study type: Interventional

This study is a randomized, open-label, oral single dosing, two-way crossover clinical trial to evaluate the effects of food on the bioavailability of CKD-397 after a single oral dose in healthy male subjects

NCT ID: NCT02592473 Recruiting - Clinical trials for Prostatic Hyperplasia

Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia

Start date: November 2015
Phase: N/A
Study type: Interventional

The purpose of this project is to evaluate the safety, efficacy, and feasibility of performing prostatic artery embolization (PAE) using endovascular techniques and particle embolics in men suffering from lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).

NCT ID: NCT02578953 Completed - Clinical trials for Prostatic Hyperplasia

Bioequivalence Study of Dutasteride Capsules in Healthy Japanese Male Subjects

Start date: September 9, 2015
Phase: Phase 1
Study type: Interventional

This will be a single center, open-label, single dose, randomized and 2-way crossover study in healthy Japanese male subjects under fasting conditions. The study will be conducted to determine the bioequivalence between dutasteride capsules manufactured at GSK (test product) and dutasteride capsule manufactured at Catalent (reference product) in healthy Japanese male subjects. Subjects will have a screening visit within 30 days prior to the first dose of study treatment, two treatment periods separated by 28-days washout period, a re-visit 10-14 days after the second dose for the first follow-up and a second follow up via telephone 50-54 days after the second dose. The total duration of the study will be approximately 15 weeks from screening to the second follow up.

NCT ID: NCT02566551 Withdrawn - Clinical trials for Benign Prostatic Hyperplasia

Prospective Controlled Randomized Study of PAE vs TURP for BPH Treatment.

Start date: October 2015
Phase: N/A
Study type: Interventional

The purpose of this prospective randomized controlled study is to compare the improvement of symptoms from benign prostatic hyperplasia (BPH) and the improvement of QoL, in patients undergoing prostatic artery embolization (PAE) or conventional transurethral resection of the prostate (TURP).

NCT ID: NCT02533687 Suspended - Clinical trials for Benign Prostatic Hypertrophy

Comparison of Different Energy Sources During TUR-P

Start date: July 2020
Phase: N/A
Study type: Interventional

With this study, it is aimed to compare the operative results and complication rates in transurethral resection of the prostate (TUR-P) performed by resectoscopes with two different bipolar and a monopolar energy sources.